Synthesis and biological evaluation of novel coumarin derivatives as antiplatelet agents

Article abstract of DOI:10.3987/COM-15-13342

In order to develop anti-thrombotic agents with higher potency, a series of novel coumarin derivatives (5a-m) were designed, synthesized and biologically evaluated. Compound 5e displayed the strongest activity in inhibiting the adenosine diphosphate (ADP)-induced platelet aggregation in vitro, with 2.3-fold more effectiveness than clinically used antiplatelet drug aspirin (ASP). Thus, Compound 5e could deserve further investigations as antiplatelet agents.

Full text of DOI:10.3987/COM-15-13342

Fig.1. MS of compound 5a
Fig.1. MS of compound 5b

Fig.3. MS of compound 5c
Fig.4. MS of compound 5d

Fig.5. MS of compound 5e
5 #26 RT: 0.21 AV: 1 NL: 7.39E6
T: FTMS + c ESIFull ms [100.00-1000.00]
318.1334
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
319.1367
315.6767
312.3260
5
0
302.3052
304.1534
292.1179
326.0441
325
346.3315
345
330.3365
330
320.1392
320
349.1832
350
338.3412
335 340
297.2924
295
286.5898
285
290
300
305
310
315
m/z
Fig.6. MS of compound 5f

Fig.7. MS of compound 5g

Fig.8. MS of compound 5h
Fig.9. MS of compound 5i

Fig.10. MS of compound 5j
Fig.11. MS of compound 5k

Fig.12. MS of compound 5l
Fig.13. MS of compound 5m